195 related articles for article (PubMed ID: 9332462)
1. Multicentre CRC phase II trial of temozolomide in recurrent or progressive high-grade glioma.
Bower M; Newlands ES; Bleehen NM; Brada M; Begent RJ; Calvert H; Colquhoun I; Lewis P; Brampton MH
Cancer Chemother Pharmacol; 1997; 40(6):484-8. PubMed ID: 9332462
[TBL] [Abstract][Full Text] [Related]
2. Phase I trial of temozolomide using an extended continuous oral schedule.
Brock CS; Newlands ES; Wedge SR; Bower M; Evans H; Colquhoun I; Roddie M; Glaser M; Brampton MH; Rustin GJ
Cancer Res; 1998 Oct; 58(19):4363-7. PubMed ID: 9766665
[TBL] [Abstract][Full Text] [Related]
3. A phase II study of extended low-dose temozolomide in recurrent malignant gliomas.
Khan RB; Raizer JJ; Malkin MG; Bazylewicz KA; Abrey LE
Neuro Oncol; 2002 Jan; 4(1):39-43. PubMed ID: 11772431
[TBL] [Abstract][Full Text] [Related]
4. Combined radiotherapy and temozolomide in patients with recurrent high grade glioma.
Schönekaes K; Mücke R; Panke J; Rama B; Wagner W
Tumori; 2002; 88(1):28-31. PubMed ID: 12004846
[TBL] [Abstract][Full Text] [Related]
5. Multi-institutional phase II study of temozolomide administered twice daily in the treatment of recurrent high-grade gliomas.
Balmaceda C; Peereboom D; Pannullo S; Cheung YK; Fisher PG; Alavi J; Sisti M; Chen J; Fine RL
Cancer; 2008 Mar; 112(5):1139-46. PubMed ID: 18246536
[TBL] [Abstract][Full Text] [Related]
6. Prolonged administration of temozolomide in adult patients with anaplastic glioma.
Freyschlag CF; Smolczyk DR; Janzen E; Schmieder K; Thomé C; Lohr F; Wenz F; Weiss C; Tuettenberg J; Seiz M
Anticancer Res; 2011 Nov; 31(11):3873-7. PubMed ID: 22110212
[TBL] [Abstract][Full Text] [Related]
7. [Favourable result for temozolomide in recurrent high-grade glioma].
Taal W; van der Rijt CD; Sillevis Smitt PA; Kros JM; van Heuvel I; Enting RH; van den Bent MJ
Ned Tijdschr Geneeskd; 2005 Jun; 149(25):1393-9. PubMed ID: 15997692
[TBL] [Abstract][Full Text] [Related]
8. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Quinn JA; Reardon DA; Friedman AH; Rich JN; Sampson JH; Provenzale JM; McLendon RE; Gururangan S; Bigner DD; Herndon JE; Avgeropoulos N; Finlay J; Tourt-Uhlig S; Affronti ML; Evans B; Stafford-Fox V; Zaknoen S; Friedman HS
J Clin Oncol; 2003 Feb; 21(4):646-51. PubMed ID: 12586801
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide and treatment of malignant glioma.
Friedman HS; Kerby T; Calvert H
Clin Cancer Res; 2000 Jul; 6(7):2585-97. PubMed ID: 10914698
[TBL] [Abstract][Full Text] [Related]
10. Temozolomide in children with progressive low-grade glioma.
Gururangan S; Fisher MJ; Allen JC; Herndon JE; Quinn JA; Reardon DA; Vredenburgh JJ; Desjardins A; Phillips PC; Watral MA; Krauser JM; Friedman AH; Friedman HS
Neuro Oncol; 2007 Apr; 9(2):161-8. PubMed ID: 17347491
[TBL] [Abstract][Full Text] [Related]
11. Temozolomide in the treatment of recurrent malignant glioma.
Chang SM; Theodosopoulos P; Lamborn K; Malec M; Rabbitt J; Page M; Prados MD
Cancer; 2004 Feb; 100(3):605-11. PubMed ID: 14745879
[TBL] [Abstract][Full Text] [Related]
12. Effects of palliative treatment with temozolomide in patients with high-grade gliomas.
Ziobro M; Rolski J; Grela-Wojewoda A; Zygulska A; Niemiec M
Neurol Neurochir Pol; 2008; 42(3):210-5. PubMed ID: 18651326
[TBL] [Abstract][Full Text] [Related]
13. Temozolomide for the treatment of recurrent supratentorial glioma: results of a compassionate use program in Belgium.
Everaert E; Neyns B; Joosens E; Strauven T; Branle F; Menten J
J Neurooncol; 2004 Oct; 70(1):37-48. PubMed ID: 15527106
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study.
Jaeckle KA; Hess KR; Yung WK; Greenberg H; Fine H; Schiff D; Pollack IF; Kuhn J; Fink K; Mehta M; Cloughesy T; Nicholas MK; Chang S; Prados M;
J Clin Oncol; 2003 Jun; 21(12):2305-11. PubMed ID: 12805331
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of two-weekly temozolomide in patients with high-grade gliomas.
Wong S; Rosenthal MA; Dowling A; Jennens R; Woods AM; Ashley D; Cher L
J Clin Neurosci; 2006 Jan; 13(1):18-22. PubMed ID: 16356721
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide in malignant gliomas of childhood: a United Kingdom Children's Cancer Study Group and French Society for Pediatric Oncology Intergroup Study.
Lashford LS; Thiesse P; Jouvet A; Jaspan T; Couanet D; Griffiths PD; Doz F; Ironside J; Robson K; Hobson R; Dugan M; Pearson AD; Vassal G; Frappaz D;
J Clin Oncol; 2002 Dec; 20(24):4684-91. PubMed ID: 12488414
[TBL] [Abstract][Full Text] [Related]
17. Temozolomide as a second-line systemic regimen in recurrent high-grade glioma: a phase II study.
Brandes AA; Ermani M; Basso U; Amistà P; Berti F; Scienza R; Rotilio A; Pinna G; Gardiman M; Monfardini S
Ann Oncol; 2001 Feb; 12(2):255-7. PubMed ID: 11300334
[TBL] [Abstract][Full Text] [Related]
18. Temozolomide: a milestone in neuro-oncology and beyond?
Mutter N; Stupp R
Expert Rev Anticancer Ther; 2006 Aug; 6(8):1187-204. PubMed ID: 16925485
[TBL] [Abstract][Full Text] [Related]
19. A phase II study of temozolomide in patients with newly diagnosed supratentorial malignant glioma before radiation therapy.
Gilbert MR; Friedman HS; Kuttesch JF; Prados MD; Olson JJ; Reaman GH; Zaknoen SL
Neuro Oncol; 2002 Oct; 4(4):261-7. PubMed ID: 12356356
[TBL] [Abstract][Full Text] [Related]
20. [A multicenter randomized controlled study of temozolomide in 97 patients with malignant brain glioma].
Qian ZZ; Wang HQ; Liu XM; Yang SY; Fu Z; Chang Y; Liu XY; Yu H
Zhonghua Yi Xue Za Zhi; 2009 Aug; 89(29):2059-62. PubMed ID: 20017331
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
